Lipocine posted a net loss of $2.6 million, or ($0.32) a share, for Q2 ended June 30, 2026, widening from a $2.2 million loss.
Revenue fell to $190,099 from $622,849, reflecting royalty revenue from TLANDO sales of $190,000 and no license revenue.
Unrestricted cash, cash equivalents and marketable investment securities climbed to $23.3 million at June 30, up from $14.9 million at year-end.
Pipeline update
The Phase 3 trial of LPCN 1154 for postpartum depression missed its primary endpoint; Lipocine scheduled an FDA guidance meeting for Q3 2026.
The company initiated a new placebo-controlled PPD study while continuing to pursue partnerships for Brlizio (LPCN 1154) and TLANDO outside key territories.
LPCN•
